Tumor response assessments with diffusion and perfusion MRI
暂无分享,去创建一个
[1] David S. Martin,et al. Diffusion and Perfusion Magnetic Resonance Imaging: Applications to Functional MRI , 1996 .
[2] E. Rostrup,et al. Measurement of the arterial concentration of Gd‐DTPA using MRI: A step toward quantitative perfusion imaging , 1996, Magnetic resonance in medicine.
[3] P. Tofts. Modeling tracer kinetics in dynamic Gd‐DTPA MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.
[4] P J Drew,et al. Microvessel density in invasive breast cancer assessed by dynamic gd‐dtpa enhanced MRI , 1997 .
[5] J. Witjes,et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. , 1998, Radiology.
[6] O Salonen,et al. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation. , 1999, Investigative radiology.
[7] Franklyn A. Howe,et al. Assessment of induced rat mammary tumour response to chemotherapy using the apparent diffusion coefficient of tissue water as determined by diffusion-weighted 1H-NMR spectroscopy in vivo , 1999 .
[8] W E Reddick,et al. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma , 1999, Journal of magnetic resonance imaging : JMRI.
[9] G Brix,et al. Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.
[10] M. Knopp,et al. Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.
[11] H K Lim,et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: usefulness of power Doppler US with a microbubble contrast agent in evaluating therapeutic response-preliminary results. , 2000, Radiology.
[12] Olav Haraldseth,et al. Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging , 2000, Magnetic resonance in medicine.
[13] J P Logue,et al. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[14] R. Edelman,et al. Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization. , 2000, Journal of magnetic resonance imaging : JMRI.
[15] R. Matsubayashi,et al. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factors. , 2000, Radiology.
[16] T. Akashi,et al. Relationship between bone marrow cellularity and apparent diffusion coefficient , 2001, Journal of magnetic resonance imaging : JMRI.
[17] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[18] D Artemov,et al. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. , 2001, Neoplasia.
[19] H Lyng,et al. Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd‐DTPA‐enhanced MR imaging , 2001, Journal of magnetic resonance imaging : JMRI.
[20] David L Buckley,et al. Uncertainty in the analysis of tracer kinetics using dynamic contrast‐enhanced T1‐weighted MRI , 2002, Magnetic resonance in medicine.
[21] A. Padhani. Dynamic contrast‐enhanced MRI in clinical oncology: Current status and future directions , 2002, Journal of magnetic resonance imaging : JMRI.
[22] Jan Wolber,et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation , 2002, The Lancet.
[23] A. Padhani,et al. Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis , 2002, NMR in biomedicine.
[24] R. Kerbel,et al. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. , 2002, Cancer research.
[25] Donna Richardson,et al. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. , 2002, Lung cancer.
[26] R. Ponzone,et al. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. , 2003, La Radiologia medica.
[27] Jürgen Griebel,et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. , 2003, International journal of radiation oncology, biology, physics.
[28] Paul A Meyers,et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. , 2003, Radiology.
[29] Martin A Lodge,et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Orhan Nalcioglu,et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer , 2003, Journal of magnetic resonance imaging : JMRI.
[31] S. Maier,et al. High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. , 2004, Radiology.
[32] D. Collins,et al. Dynamic magnetic resonance imaging of tumor perfusion , 2004, IEEE Engineering in Medicine and Biology Magazine.
[34] R. Gillies,et al. Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. , 2004, Neoplasia.
[35] C. Boesch,et al. Diffusion‐weighted imaging of the parotid gland: Influence of the choice of b‐values on the apparent diffusion coefficient value , 2004, Journal of magnetic resonance imaging : JMRI.
[36] A. Padhani,et al. Perfusion MR Imaging of Extracranial Tumor Angiogenesis , 2004, Topics in magnetic resonance imaging : TMRI.
[37] An investigation of DCE-MRI as a non-invasive measure of angiogenesis in rectal cancer , 2004 .
[38] David J Collins,et al. Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. , 2004, IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society.
[39] J E Husband,et al. Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.
[40] C. Meyer,et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] Y. Ni,et al. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. , 2005, Radiology.
[42] J R Griffiths,et al. Clinical studies. , 2005, Advances in pharmacology.
[43] Robert J Gillies,et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478. , 2005, Neoplasia.
[44] Y. Ni,et al. Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. , 2005, Neoplasia.
[45] Philippe Lambin,et al. Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. , 2005, International journal of radiation oncology, biology, physics.
[46] Kevin Camphausen,et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] Mathias Langer,et al. Osteosarcoma: Preliminary Results of In Vivo Assessment of Tumor Necrosis After Chemotherapy With Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging , 2006, Investigative radiology.
[48] V. V. van Hinsbergh,et al. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton , 2006, Molecular Cancer Therapeutics.
[49] Frederik De Keyzer,et al. Extracranial applications of diffusion-weighted magnetic resonance imaging , 2007, European Radiology.
[50] Peter Gibbs,et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.
[51] John Suckling,et al. Informatics in Radiology (infoRAD): Magnetic Resonance Imaging Workbench: analysis and visualization of dynamic contrast-enhanced MR imaging data. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.
[52] A R Padhani,et al. Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. , 2006, The British journal of radiology.
[53] I. Wilkinson,et al. Dexamethasone and Enhancing Solitary Cerebral Mass Lesions: Alterations in Perfusion and Blood-tumor Barrier Kinetics Shown by Magnetic Resonance Imaging , 2006, Neurosurgery.
[54] Carmel Hayes,et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. , 2006, Radiology.
[55] D J Collins,et al. Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis , 2006, Physics in medicine and biology.
[56] S. Steinberg,et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. , 2007, Radiology.
[57] Haesun Choi,et al. We should desist using RECIST, at least in GIST. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] John A Butman,et al. Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. , 2007, Neoplasia.
[59] Neil J Sebire,et al. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. , 2007, Radiology.
[60] B. Ross,et al. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] D. Collins,et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. , 2007, AJR. American journal of roentgenology.
[62] T. Yankeelov,et al. Measuring Tumor Perfusion in Control and Treated Murine Tumors , 2007, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[63] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[64] Timothy D Johnson,et al. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. , 2007, Neoplasia.
[65] G. Parker,et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.
[66] D. Collins,et al. Dynamic MRI for imaging tumor microvasculature: Comparison of susceptibility and relaxivity techniques in pelvic tumors , 2007, Journal of magnetic resonance imaging : JMRI.
[67] Robert A. Beckman,et al. Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[68] Anwar R. Padhani,et al. Physiological changes within the prostate caused by androgen withdrawal , 2007 .
[69] D J Collins,et al. Reproducibility of reference tissue quantification of dynamic contrast-enhanced data: comparison with a fixed vascular input function , 2007, Physics in medicine and biology.
[70] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[71] D. Collins,et al. Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.
[72] Geoff J M Parker,et al. Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.
[73] L. Shen,et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. , 2008, Radiology.
[74] T. Chenevert,et al. Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. , 2008, Translational oncology.
[75] D. Mankoff,et al. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer. , 2008, Academic radiology.
[76] Bernd Hamm,et al. Diffusion‐weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft‐tissue sarcomas , 2008, Journal of magnetic resonance imaging : JMRI.
[77] Timothy D Johnson,et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] E. Squillaci,et al. Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T , 2008, La radiologia medica.
[80] Andreas Makris,et al. Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2008, Clinical Cancer Research.
[81] Gregory Karczmar,et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] K. Flaherty,et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma , 2008, Cancer biology & therapy.
[83] David J Collins,et al. Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapy , 2008, Nature Clinical Practice Oncology.
[84] Martin O. Leach,et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial , 2009, European Radiology.
[85] Bradford A Moffat,et al. A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. , 2009, Translational oncology.
[86] C. Claussen,et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. , 2009, AJR. American journal of roentgenology.
[87] Gary Liney,et al. Correlation of diffusion‐weighted magnetic resonance data with cellularity in prostate cancer , 2009, BJU international.
[88] Kevin Harrington,et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. , 2009, International journal of radiation oncology, biology, physics.
[89] T. Mikkelsen,et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker , 2010, Journal of Neuro-Oncology.
[90] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[91] Steinar Lundgren,et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE‐MRI , 2009, Journal of magnetic resonance imaging : JMRI.
[92] P. Choyke,et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. , 2009, Neoplasia.
[93] Yanlei Li,et al. Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation. , 2009, Clinical radiology.
[94] David A Bluemke,et al. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. , 2009, Radiology.
[95] U. Sharma,et al. Longitudinal study of the assessment by MRI and diffusion‐weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy , 2009, NMR in biomedicine.
[96] Bin Wang,et al. Diffusion‐weighted imaging of prostate cancer: Correlation between apparent diffusion coefficient values and tumor proliferation , 2009, Journal of magnetic resonance imaging : JMRI.
[97] R. Kauppinen,et al. Monitoring of gliomas in vivo by diffusion MRI and 1H MRS during gene therapy‐induced apoptosis: interrelationships between water diffusion and mobile lipids , 2009, NMR in biomedicine.
[98] T. Hirai,et al. The value of diffusion-weighted imaging for monitoring the chemotherapeutic response of osteosarcoma: a comparison between average apparent diffusion coefficient and minimum apparent diffusion coefficient , 2010, Skeletal Radiology.
[99] Brandon Whitcher,et al. Quantifying spatial heterogeneity in dynamic contrast‐enhanced MRI parameter maps , 2009, Magnetic resonance in medicine.
[100] J. Machan,et al. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. , 2010, AJR. American journal of roentgenology.
[101] G. Parker,et al. Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[102] Woo Kyung Moon,et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. , 2010, Radiology.
[103] Thomas Benner,et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] B. Fallone,et al. Monitoring T2 and ADC at 9.4 T following fractionated external beam radiation therapy in a mouse model , 2010, Physics in medicine and biology.
[105] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[106] C. Koch,et al. Early detection of radiation therapy response in non‐Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging , 2010, NMR in biomedicine.
[107] Lei Tang,et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. , 2010, Radiology.
[108] Brian D Ross,et al. Predicting and monitoring cancer treatment response with diffusion‐weighted MRI , 2010, Journal of magnetic resonance imaging : JMRI.
[109] A. Padhani,et al. Multiparametric imaging of tumor response to therapy. , 2010, Radiology.
[110] Y. Kajiya,et al. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[111] N. deSouza,et al. Diffusion Weighted Magnetic Resonance Imaging of metastatic bone disease: A biomarker for treatment response monitoring. , 2010, Cancer biomarkers : section A of Disease markers.
[112] P. LaViolette,et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity , 2010, Journal of magnetic resonance imaging : JMRI.
[113] Anwar R. Padhani,et al. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[114] H. Goldschmidt,et al. Diffusion‐weighted imaging for non‐invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology , 2011, British journal of haematology.
[115] Baris Turkbey,et al. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? , 2011, Radiology.
[116] Andreas Makris,et al. Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. , 2011, Radiology.
[117] A. Maia,et al. Diffusion MR imaging for monitoring treatment response. , 2011, Neuroimaging clinics of North America.